ICER issues affordability and access alert for tardive dyskinesia drugs

The Institute for Clinical and Economic Review issued an affordability and access alert for tardive dyskinesia drugs Ingrezza valbenazine (MT-5199, NBI-98854) and Austedo deutetrabenazine (SD-809), saying the drugs far exceed ICER’s budget impact threshold at their current wholesale acquisition costs (WAC). The alert was published in the institute’s final evidence report on the drugs on Dec. 22.

ICER said the cost of the drugs “may be difficult for the health care system to absorb over the short term without displacing other needed services or contributing to rapid growth in health care insurance costs.”...